These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3838925)

  • 1. BMY28142, cefbuperazone (T-1982), and Sch 34343. Antimicrobial activity against 94 anaerobes compared to seven other antimicrobial agents.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1985 May; 3(3):263-8. PubMed ID: 3838925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
    Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of susceptibility results of the Bacteroides fragilis group and other anaerobes by traditional MIC results and statistical methods.
    Aldridge KE; Johnson WD
    J Antimicrob Chemother; 1997 Mar; 39(3):319-24. PubMed ID: 9096180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
    Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria.
    Shafran SD; Wong J; Chow AW
    Antimicrob Agents Chemother; 1985 May; 27(5):749-52. PubMed ID: 4015069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter study of the in vitro antianaerobic activity of cefotetan compared with other antimicrobial agents.
    Zabransky RJ; Bobey DG; Sheikh W
    Am J Surg; 1988 May; 155(5A):47-51. PubMed ID: 3163901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
    Hoellman DB; Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Mar; 42(3):495-501. PubMed ID: 9517922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European collaborative study of reproducibility of quantitative sensitivity testing of anaerobes.
    King A; Phillips I
    J Antimicrob Chemother; 1988 Apr; 21(4):425-38. PubMed ID: 3378957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes.
    Werner H; Heizmann W; Luft G
    Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of anaerobic bacteria from the intestinal microflora of healthy children and antimicrobial-treated children in Nicaragua.
    Cáceres M; Carera E; Palmgren AC; Nord CE
    Rev Esp Quimioter; 1998 Sep; 11(3):221-8. PubMed ID: 9795308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefbuperazone, a new cephamycin, against anaerobic bacteria.
    Prabhala RH; Thadepalli H; Rao B; Bansal MB; Marshall R
    Antimicrob Agents Chemother; 1985 Apr; 27(4):640-2. PubMed ID: 4004195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefbuperazone against anaerobic bacteria.
    Wexler H; Carter WT; Harris BH; Finegold SM
    Antimicrob Agents Chemother; 1985 Apr; 27(4):674-6. PubMed ID: 3847274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in-vitro activity of Sch 34343 for a wide spectrum of clinically significant anaerobic bacteria.
    Wells CL; Wilkins TD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():177-82. PubMed ID: 4030546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of SCH 34343 against anaerobic bacteria.
    Sutter VL; Wexler H; Finegold SM
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):341-4. PubMed ID: 3698546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro effect of piperacillin, amoxicillin, cefoxitin and metronidazole against obligate anaerobic bacteria].
    Derriennic M; Reynaud A; Launay C; Courtieu AL
    Presse Med; 1986 Dec; 15(46):2279-81. PubMed ID: 2949268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
    Betriu C; Cabronero C; Gomez M; Picazo JJ
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of antimicrobial resistance and resistance transfer in anaerobic bacteria.
    Tally FP; Malamy MH
    Scand J Infect Dis Suppl; 1982; 35():37-44. PubMed ID: 6300995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.